Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.

In English

Författare

Summary, in English

The purpose of this study was to investigate the prognostic implications of BCL6 rearrangement in a uniformly treated population of patients with diffuse large B-cell lymphoma (DLBCL) and to characterise the relationship between BCL6 rearrangement and prognostic factors. A total of 269 patients with DLBCL entered a randomised trial comparing the chemotherapy regimen CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) to the MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin) regimen. In 44 cases, frozen tissue was available for assessment of BCL6 status by Southern blot analysis. BCL6 was rearranged in six of 43 evaluable cases (14%), and was associated with elevated lactate dehydrogenase (LDH), and a higher patient age. No association between BCL6 status and expression of BCL2, Ki-67 or TP53 was found. Patients presenting with BCL6 rearrangement displayed a weak trend towards better overall and failure-free survival (67 and 67% at 5 years), compared to patients with germline BCL6 (63 and 52%), but the difference was not statistically significant. In accordance with previously published series, the presence of BCL6 rearrangement does not define a prognostically distinct subgroup of DLBCL. Assessment of BCL6 status may, however, be of clinical interest when related to other prognostic variables.

Publiceringsår

2002

Språk

Engelska

Sidor

161-165

Publikation/Tidskrift/Serie

International Journal of Oncology

Volym

20

Issue

1

Dokumenttyp

Artikel i tidskrift

Förlag

Spandidos Publications

Ämne

  • Cancer and Oncology

Nyckelord

  • Gene Rearrangement B-Lymphocyte : genetics
  • Human
  • Immunophenotyping
  • Lymphoma B-Cell : drug therapy : genetics
  • Leucovorin : therapeutic use
  • Lactate Dehydrogenase : metabolism
  • Lymphoma Large-Cell Diffuse : drug therapy : genetics
  • Male
  • Methotrexate : therapeutic use
  • Middle Age
  • Neoplasm Staging
  • Prednisone : therapeutic use
  • Prognosis
  • Proto-Oncogene Proteins : genetics
  • Support Non-U.S. Gov't
  • Vincristine : therapeutic use
  • Transcription Factors : genetics
  • Doxorubicin : therapeutic use
  • DNA-Binding Proteins : genetics
  • DNA Neoplasm : analysis : metabolism
  • Cyclophosphamide : therapeutic use
  • Blotting Southern
  • Bleomycin : therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols : therapeutic use
  • Aged
  • Adolescence
  • Adult

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 1019-6439